文献速递淋巴瘤

直接抗病毒药物在HIV相关非霍奇金淋巴瘤合并HCV感染中的作用

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.
PubMed 文献 · Br J Haematol · 2026-09-04

这项回顾性研究纳入67例HIV合并HCV的NHL患者(48例DLBCL),多数接受免疫化疗。DAA组5年OS优于未用组(81% vs 48%,p=0.035),多因素分析中DAA影响边缘显著(p=0.055)。

要点

  • HIV合并HCV的NHL患者中,免疫化疗期间或之后使用DAA可行、安全且SVR率高。
  • DAA组5年OS为81%,未用组为48%(p=0.035),但多因素分析仅边缘显著。
  • 高龄aaIPI、HIV评分3-6、女性及未用利妥昔单抗是OS独立危险因素。

核心结论

  • 在HIV相关NHL合并HCV感染的高危人群中,免疫化疗期间或之后使用DAA可行、安全且高度有效。
  • DAA组5年OS优于未用DAA组,但多因素分析中DAA对OS的影响为边缘显著(p=0.055)。

研究设计与样本

  • 回顾性研究,纳入2010-2024年间14个意大利中心连续的67例HIV合并HCV的NHL患者,其中48例为DLBCL。
  • 所有患者均接受联合抗逆转录病毒治疗(ART),中位年龄51岁,男性占91%,注射吸毒者占70%。

主要发现

  • 94%的患者接受了根治性一线免疫化疗(I-CT),主要为R-CHOP方案。
  • 2016年后26例患者接受DAA(8例与I-CT同步,18例在I-CT后),DAA毒性轻微,所有病例均获得持续病毒学应答(SVR)。
  • 中位随访91个月,3年总生存(OS)率为61%。
  • DAA治疗组5年OS为81%,未用DAA组为48%(p=0.035),同步或后续使用DAA无差异。
  • 多因素分析显示高龄调整的国际预后指数(aaIPI)高、HIV评分3-6、女性及未接受利妥昔单抗治疗是OS的独立危险因素。

临床怎么用

  • 对于HIV相关NHL合并HCV感染的患者,可考虑在免疫化疗期间或之后使用DAA,以改善生存。
  • DAA治疗在此高危人群中安全可行,且SVR率高,支持其临床应用。

局限性

  • 回顾性研究设计,样本量较小(67例),可能存在选择偏倚。
  • DAA对OS的独立影响在多因素分析中仅为边缘显著(p=0.055),需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis C virus (HCV) infection is common among patients with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL). Although direct-acting antivirals (DAAs) achieve high sustained virological response (SVR) rates, data on their effects in people with HIV and HCV and affected by NHL remain limited. We conducted a retrospective study of 67 consecutive NHL patients with HIV and HCV (48 diffuse large B-cell lymphoma [DLBCL]) treated at 14 Italian centres (2010-2024). All patients received concomitant anti-retroviral therapy (ART). The median age was 51 years. The majority of patients were male (91%) and people who inject drugs (70%). Most patients (94%) received curative first-line immunochemotherapy (I-CT), mainly rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). After 2016, 26 patients received DAAs (8 concurrently, 18 after I-CT). DAA toxicity was minimal, and SVR was achieved in all cases. With a median follow-up of 91 months, the 3-year overall survival (OS) was 61%. Patients treated with DAAs had better 5-year OS (81% vs. 48%, p = 0.035), with no difference between those who received DAAs subsequently or concurrently with I-CT. Multivariate analysis identified high age-adjusted International Prognostic Index (aaIPI), HIV score 3-6, female sex and absence of rituximab treatment as independent risk factors for OS, while DAAs had a borderline impact (p = 0.055). In conclusion, DAA therapy during or after I-CT is feasible, safe and highly effective in this high-risk group.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Merli M, Bianchi B, Bibas M, et al. Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi. Br J Haematol. 2026. PMID: 42697852. doi:10.1111/bjh.70793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。